Silviu Itescu is the CEO and Founder of Mesoblast, the stem cell business, which has been a huge rollercoaster for shareholders. Alan Kohler spoke to Silviu to find out why their latest phase 2 trial results were taken so poorly by the market.
Alan Kohler is one of Australia’s most respected finance reporters. For decades readers and viewers have enjoyed his expert opinion in press, television and of course on line. His writing and interviews bring a context to the issues that matter to investors, with a personality that is often missing from other financial experts. Alan started The Constant Investor to be able to directly share his passion for discovering exciting companies.